Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 215-220

  Hong, Junshik ^a   Jung, Minkyu ^a   Kim, Yu Jin ^a   Sym, Sun Jin ^a   Kyung, Sun Young ^a   Park, Jinny ^a   Lee, Sang Pyo ^a   Park, Jeong Woong ^a   Cho, Eun Kyung ^a   Jeong, Sung Hwan ^a   Shin, Dong Bok ^a   Lee, Jae Hoon ^a  

^a Gachon University   (South Korea)

Author keywords

Belotecan; Chemotherapy; Cisplatin; Small cell lung carcinoma

Indexed keywords

BELOTECAN; CDK 602; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ADRENAL METASTASIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW METASTASIS; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LUNG SMALL CELL CANCER; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856700926     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1689-6     Document Type: Article

References (18)

1. R Govindan N Page D Morgensztern W Read R Tierney A Vlahiotis EL Spitznagel J Piccirillo 2006 Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 4539 4544 17008692 10.1200/JCO.2005.04.4859 (Pubitemid 46630948)
2. DM Jackman BE Johnson 2005 Small-cell lung cancer Lancet 366 1385 1396 16226617 10.1016/S0140-6736(05)67569-1 1:CAS:528:DC%2BD2MXhtFSmsbrO (Pubitemid 41443406)
3. JR Eckardt J von Pawel Z Papai A Tomova V Tzekova TE Crofts S Brannon P Wissel G Ross 2006 Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer J Clin Oncol 24 2044 2051 16648504 10.1200/JCO.2005.03.3332 1:CAS:528: DC%2BD28Xlt1amurs%3D (Pubitemid 46622113)
4. N Hanna PA Bunn Jr C Langer L Einhorn T Guthrie Jr T Beck R Ansari P Ellis M Byrne M Morrison S Hariharan B Wang A Sandler 2006 Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24 2038 2043 16648503 10.1200/JCO.2005.04.8595 1:CAS:528:DC%2BD28Xlt1amuro%3D (Pubitemid 46622112)
5. PN Lara Jr R Natale J Crowley HJ Lenz MW Redman JE Carleton J Jett CJ Langer JP Kuebler SR Dakhil K Chansky DR Gandara 2009 Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 J Clin Oncol 27 2530 2535 19349543 10.1200/JCO.2008.20.1061 1:CAS:528: DC%2BD1MXmvVOhsbo%3D
6. K Noda Y Nishiwaki M Kawahara S Negoro T Sugiura A Yokoyama M Fukuoka K Mori K Watanabe T Tamura S Yamamoto N Saijo 2002 Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 85 91 11784874 10.1056/NEJMoa003034 1:CAS:528: DC%2BD38Xkt1OlsA%3D%3D (Pubitemid 34438898)
7. JH Lee JM Lee JK Kim SK Ahn SJ Lee MY Kim SS Jew JG Park CI Hong 1998 Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor Arch Pharm Res 21 581 590 9875499 10.1007/BF02975379 1:CAS:528:DyaK1cXms1ektLo%3D (Pubitemid 128668322)
8. JH Lee JM Lee KH Lim JK Kim SK Ahn YJ Bang CI Hong 2000 Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative Ann N Y Acad Sci 922 324 325 11193913 10.1111/j.1749-6632.2000.tb07055.x 1:CAS:528:DC%2BD3MXntVGjsg%3D%3D (Pubitemid 32050270)
9. JY Jung SH Song TY Kim JH Park HS Jong SA Im YJ Bang NK Kim 2006 The synergism between Belotecan and cisplatin in gastric cancer Cancer Res Treat 38 159 167 19771277 10.4143/crt.2006.38.3.159
10. SJ Kim JS Kim SC Kim YK Kim JY Kang HK Yoon JS Song SH Lee HS Moon JW Kim KH Kim CH Kim BY Shim HK Kim 2010 A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer Lung Cancer 68 446 449 19683359 10.1016/j.lungcan.2009.07.002 1:STN:280:DC%2BC3czgs1Shug%3D%3D
11. DH Lee SW Kim C Suh JS Lee JH Lee SJ Lee BY Ryoo K Park JS Kim DS Heo NK Kim 2008 Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study Ann Oncol 19 123 127 17823384 10.1093/annonc/mdm437 1:STN:280:DC%2BD1c%2FgtVagtg%3D%3D
12. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
13. A Hermes B Bergman R Bremnes L Ek S Fluge C Sederholm S Sundstrom L Thaning J Vilsvik U Aasebo S Sorenson 2008 Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial J Clin Oncol 26 4261 4267 18779613 10.1200/JCO.2007.15.7545 1:CAS:528:DC%2BD1cXhtF2it7bE
14. Kim YS, Park SH, Kyung SY, Sym SJ, Lee SP, Park JW, Jung SH, Park J, Cho EK, Lee JH, Shin DB (2011) Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer. Med Oncol 28:342-350
15. H Okamoto K Naoki Y Narita N Hida H Kunikane K Watanabe 2006 A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer Lung Cancer 53 197 203 16781005 10.1016/j.lungcan.2006.05.004 (Pubitemid 44040902)
16. Schmittel AH, Sebastian M, Fischer von Weikersthal L, Gauler T, Hortig P, Fischer JR, Link H, Binder D, Eberhardt W, Keilholz U, Germany A (2009) Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: results of the German randomized phase III trial. J Clin Oncol 25: 15s (suppl; abstr 8029)
17. DH Lee SW Kim C Suh JS Lee JS Ahn MJ Ahn K Park II Na JC Lee BY Ryoo SH Yang 2010 Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer Cancer 116 132 136 19904804 1:CAS:528:DC%2BC3cXitFGitbg%3D
18. TJ Smith J Khatcheressian GH Lyman H Ozer JO Armitage L Balducci CL Bennett SB Cantor J Crawford SJ Cross G Demetri CE Desch PA Pizzo CA Schiffer L Schwartzberg MR Somerfield G Somlo JC Wade JL Wade RJ Winn AJ Wozniak AC Wolff 2006 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187 3205 16682719 10.1200/JCO.2006.06.4451 1:CAS:528:DC%2BD28XnslKhsLo%3D (Pubitemid 46638957)